PRESS RELEASE
News
-
-
PRESS RELEASE
EQS-Adhoc: Allgeier SE: Evora acquires SAP cloud ERP expert all4cloud – expansion of the Allgeier SAP portfolio and public cloud strategy
Allgeier SE strengthens its SAP portfolio with the acquisition of all4cloud by Evora, enhancing its public cloud strategy and expanding its enterprise solutions -
PRESS RELEASE
EQS-Adhoc: JDC Group AG successfully places a new senior secured bond with a volume of EUR 70 million.
JDC Group AG successfully places a new senior secured bond of EUR 70 million under Norwegian law. Bond bears interest at EURIBOR plus 4.5% p.a. Oversubscribed due to strong investor demand. Bonds to trade on Euronext ABM and Frankfurt Stock Exchange -
-
-
-
PRESS RELEASE
Original-Research: Energiekontor AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH has updated its recommendation on Energiekontor AG, reiterating a Buy rating with a target price of EUR 105.00. The company's strong performance in H1 is highlighted, with an expected EBT guidance of €70m - €90m for 2025 -
PRESS RELEASE
New to The Street's Esteemed Client Synergy CHC Corp. (NASDAQ: SNYR) Announces Nationwide EG America Rollout for FOCUSfactor(R) Focus + Energy EG America, 6th Largest U.S. Convenience Chain, Expands Distribution Across 1,600+ High-Traffic Locations
Synergy CHC Corp. announced a significant nationwide retail expansion for FOCUSfactor Focus + Energy beverage line through EG America convenience stores, tapping into booming functional beverage market -
PRESS RELEASE
SonicStrategy Expands Exposure to 38.8 Million S Tokens Across Staking, Delegation, and DeFi Holdings, Reinforcing Institutional Alignment and Long-Term Yield Strategy
SonicStrategy Inc., subsidiary of Spetz Inc., achieves 158% increase in network exposure, reaching 38.8 million S tokens. Validator secures Sonic blockchain, engages in DeFi strategies -
PRESS RELEASE
A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
NanoViricides, Inc. reports NV-387 antiviral drug could reduce metastatic cancer resurgence caused by viral infections. NV-387 completed Phase I trial, advancing to Phase II
